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ABSTRAK 
 
Pengenalan  
Diabetik makular edema adalah salah satu komplikasi diabetes pada mata yang boleh 
menyebabkan  kebutaan. Rawatan bagi penyakit ini adalah terapi laser. Keradangan 
yang berpanjangan juga memainkan peranan penting di dalam penyakit diabetik 
makular edema. Madu tualang mengandungi  anti-inflammasi dan anti-oksidan dan 
berkeupayaan sebagai terapi tambahan untuk merawat diabetik makular edema. 
 
Objektif 
Matlamat kajian ini adalah untuk membandingkan perbezaan ketajaman penglihatan 
terbaik LogMAR (LogMAR BCVA) dan ketebalan pusat makula (CMT) selepas 3 
bulan rawatan menggunakan 2 kaedah berbeza iaitu gabungan rawatan terapi laser dan 
pemakanan madu tualang dan kaedah rawatan monoterapi laser ke atas pesakit  
diabetik makular edema. 
 
Metodologi 
Kajian ini merupakan kajian prospektif terkawal secara rawak yang dijalankan di 
Hospital Universiti Sains Malaysia antara April 2013 dan Ogos 2015. Pesakit yang 
menghidapi diabetik makular edema telah dipilih dan dibahagi secara rawak dengan 
menggunakan teknik rawak sampul surat kepada 2 kumpulan iaitu kumpulan laser 
tanpa madu dan kumpulan laser dan madu tualang. Pesakit dinilai LogMAR BCVA 
dan CMT sebelum dan 3 bulan selepas rawatan. LogMAR BCVA dinilai dengan 
menggunakan carta LogMAR manakala CMT dinilai dengan menggunakan mesin 
OCT Heidelberg Spectralis. 
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Keputusan 
Seramai 52 orang pesakit (kumpulan laser tanpa madu: 26 orang pesakit dan kumpulan 
laser dan madu: 26 orang pesakit) telah dipilih untuk kajian ini. Selepas 3 bulan 
rawatan dibuat, didapati peningkatan penglihatan purata LogMAR BCVA yang ketara 
pada pesakit diabetik makular edema yang dirawat dengan laser sahaja (p= 0.002). 
Walau bagaimanapun, didapati tiada perbezaan yang ketara purata LogMAR BCVA 
pada pesakit dirawat dengan laser antara mereka dengan dan tanpa madu pada 3 bulan 
selepas rawatan (p = 0.448). Tiada perbezaan ketara penurunan ketebalan makula 
direkodkan bagi nilai purata CMT (p = 0.881) pada 3 bulan selepas rawatan laser 
antara mereka dengan dan tanpa madu. Tiada pesakit yang mengalami kesan 
sampingan dari pemakanan madu tualang. 
 
Kesimpulan 
Pemakanan madu tualang sebagai terapi tambahan kepada rawatan laser fokal/grid 
menunjukkan tiada kelebihan peningkatan dari segi tahap ketajaman penglihatan dan 
penurunan ketebalan makula bila dibandingkan dengan rawatan monoterapi laser 
fokal/grid.  
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ABSTRACT 
 
Introduction 
Diabetic macular oedema (DMO) is a significant cause of vison loss in the diabetic 
patients. Laser is the standard treatment for DMO. Chronic inflammatory also has an 
important role in the pathogenesis of DMO. Tualang honey with anti-inflammatory and 
anti-oxidant properties has a potential as an adjunct treatment for DMO. 
 
Objective 
To compare LogMAR best corrected visual acuity (BCVA) and central macular 
thickness (CMT) at 3 months post laser treatment between those with and without 
honey supplement in DMO. 
 
Methods 
A prospective randomized controlled study was conducted in Hospital Universiti Sains 
Malaysia between April 2013 and August 2015. Patient with clinically significant 
macular oedema (CSMO) was selected and was randomized by using randomised 
envelope technique into 2 groups; laser without honey group and laser with honey 
group. Patients were evaluated for LogMAR BCVA and CMT pre treatment and at 3 
months post treatment. LogMAR BCVA was assessed using LogMAR chart and CMT 
was measured using Heidelberg Spectralis OCT. 
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Results 
A total of 52 patients were recruited (laser group without honey: 26 patients and laser 
with honey group: 26 patients) into this study. There was a significant improvement of 
mean LogMAR BCVA at 3 months post treatment in DMO patients treated with laser 
alone  (p=0.002). However, there was no significant difference of the mean LogMAR 
BCVA in DMO patients treated with laser between those with and without honey 
supplement at 3 months post treatment (p=0.448). There was also no significant 
difference of mean CMT (p=0.881) at 3 months post laser treatment between those with 
and without honey supplement. There was no side effect of honey noted in patients 
consumed tualang honey. 
 
Conclusion 
Tualang honey used as adjunct with standard focal/grid laser has no additional 
improvement in both visual acuity and CMT compared to laser alone. 
 
 
 
 
 
  
 
 
 
 
 
 
                             Chapter 1    
                        Introduction 
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1.1 INTRODUCTION 
Diabetic macular oedema (DMO), which can occur at any stage of diabetic 
retinopathy, is the main cause of vision loss in diabetic patient. A higher incidence of 
DMO is reported in older patients with type 2 DM (Bhagat et al., 2009).  
 
The standard treatment of DMO is laser photocoagulation proposed by Early 
Treatment Diabetic Retinopathy Study (ETDRS). In current approach for the treatment 
of DMO, intravitreal steroid and intravitreal anti vascular endothelial growth factor 
(VEGF) are other treatment modalities in clinical practice for DMO patients who do 
not respond adequately or who are refractory to laser photocoagulation. These 
therapeutic agents targeted at inflammatory mediators in which chronic inflammation 
is thought to be involved in the pathogenesis of DMO (Adamis and Berman, 2008; 
Antonetti et al., 2006). 
 
Several potential anti-inflammatory agent and anti-oxidant had been studied for the 
treatment of diabetic microvascular complication including retinopathy, nephropathy 
(Kowluru and Kennedy, 2001) and neuropathy (Haak et al., 2000). 
 
Honey is being recognized to have hypoglycemic effect when combined with 
conventional antidiabetic drug (Al-Waili, 2004; Erejuwa, 2012). Honey contains both 
anti-oxidants and anti-inflammatory properties. Thus, honey with its diversity of anti-
oxidants has a potential as adjunct treatment to DMO patients. The aim of this study is 
to evaluate the effect of  honey supplementation post focal laser in DMO. 
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1.2 BACKGROUND 
 
1.2.1 Diabetic Macular Oedema 
Diabetes mellitus (DM) is a chronic metabolic disorder with the total number of 
people with diabetes is projected to rise from 171 million in 2000 to 366 million in 
2030 (Wild et al., 2004). There is a rising prevalence of diabetes in Asian region with 
estimated 100 million people in China and 80 million in India (Shaw et al., 2010; 
Yang et al., 2010). According to the International Diabetes Federation, there were 3.2 
millon of DM cases in Malaysia in 2014 and the prevalence of diabetes in adults in 
Malaysia was 16.6% (IDF, 2014). The rising prevalence of diabetes is due to change 
of lifestyle and aging population. In other studies, there was a significant difference in 
the prevalence of diabetes between Chinese (11.5%), Malay (17.1%) and Indian 
(21.6%) in Singapore (Chiang PP, 2011). 
 
The prevalence of diabetic retinopathy increases with duration of diabetes. Nearly all 
type 1 DM and more than 60% of types 2 DM have retinopathy after 20 years (Klein 
et al., 1998). Over 10 years, macular oedema will develop in 10% of patient with 
known diabetes (Ferris and Patz, 1984). In persons with diabetes, the overall 
prevalence of DMO was 5.7% (Wong et al., 2008). The prevalence of sight 
threatening diabetic retinopathy in Malaysia reported by the National Eye Database 
(NED) in year 2007 and 2008 was 15.6% and 11.5%, respectively (Goh, 2008).  
 
DMO is the most common cause of long term visual loss in diabetic retinopathy 
(ETDRS, 1985). DMO occurs as a result of exudation of fluid, lipoprotein and other 
plasma constituent from increased vascular permeability of microaneurysm and 
defective small vessel.  
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At initial stage of DMO, the cellular distortion is reversible. However, chronic 
leakages from extensive hard exudate deposition or cystoid degeneration in fovea lead 
to permanent loss of vision. 
 
DMO can be classified into focal or diffuse oedema. Focal oedema is a well-
circumscribed retinal leakage from microaneurysm associated with complete or 
incomplete perifoveal hard exudates. On the other hand, diffuse oedema is a diffuse 
retinal thickening with severe oedema caused by leakage from capillary dilation.  
 
Clinically significant macular oedema (CSMO) is a form of DMO which is defined as 
the presence of one or more of the following features (ETDRS, 1987): 
 Retinal thickening at or within 500 µm of center of the macula (Figure 1.1) 
 Exudates at or within 500 µm of center of the macula with adjacent retinal   
thickening (Figure 1.2) 
 A zone or zones of retinal thickening of one disc area or larger, any part of which 
is within one disc diameter from the center of the macula (Figure 1.3) 
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 CHAPTER 5: Retinal Vascular Disease. 117 
Figure 5-7 Clinically significant macular edema (CSME). Retinal edema located at or within 
500 of the center of the macula. (Counesy of the ETDR5') 
Figure 5-8 CSME. Hard exudates at or within 500 of the center of the macula if associated 
with thickening of the adjacent retina. (Counesy of the ETDRS.) 
Figure 5-9 CSME. A zone of thickening larger than 1 disc area if located within 1 disc diameter 
of the center of the macula. (Courtesy of the ETDRS. ) 
 
Figure 1.1:  CSMO. Retinal thickening at or within 500 µm of center of the macula 
 
CHAPTER 5: Retinal Vascular Disease. 117 
Figure 5-7 Clinically significant macular edema (CSME). Retinal edema located at or within 
500 of the center of the macula. (Counesy of the ETDR5') 
Figure 5-8 CSME. Hard exudates at or within 500 of the center of the macula if associated 
with thickening of the adjacent retina. (Counesy of the ETDRS.) 
Figure 5-9 CSME. A zone of thickening larger than 1 disc area if located within 1 disc diameter 
of the center of the macula. (Courtesy of the ETDRS. ) 
 
Figure 1.2: CSMO.  Exudates at or within 500 µm of center of the macula with 
adjacent retinal thickening 
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Figure 5-7 Clinically significant macular edema (CSME). Retinal edema located at or within 
500 of the center of the macula. (Counesy of the ETDR5') 
Figure 5-8 CSME. Hard exudates at or within 500 of the center of the macula if associated 
with thickening of the adjacent retina. (Counesy of the ETDRS.) 
Figure 5-9 CSME. A zone of thickening larger than 1 disc area if located within 1 disc diameter 
of the center of the macula. (Courtesy of the ETDRS. ) 
 
Figure 1.3:  CSMO. A zone or zones of retinal thickening of one disc area or larger, 
any part of which is within one disc diameter from the center of macula 
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1.2.2 Pathophysiology of DMO 
The pathogenesis of DMO is complex and involves multiple factors. It occurs mainly 
as a result of disruption of the blood retinal barrier, which leads to increased 
accumulation of fluid within the intraretinal layers of the macula. Vasoactive factors 
such as VEGF, protein kinase C, histamine and other factors that are related to 
hypoxia and chronic hyperglycemia may cause breakdown of the vitreoretinal barrier. 
The abnormalities in the structure of the vitreoretinal interface may also play an 
important role in the pathogenesis of DMO. DMO may exacerbated in the presence of 
vitreomacular traction (Bhagat et al., 2009). 
 
Inflammations play an important role in molecular mechanism in the pathogenesis of 
diabetic retinopathy. Retinal inflammation starts very early and within one week of 
experimental diabetic, was noted that the accumulation of  leucocyte in the retinal 
vasculature (Adamis, 2002 ). 
 
Hyperglycemia induced diabetic retinopathy is related to 4 main biochemical 
alterations; 
i. increased polyol pathway flux 
ii. increased advanced glycation end product (AGE) formation 
iii. activation of protein kinase C isoforms 
iv. increased hexosamine pathway flux 
 
These pathways lead to increased oxidative stress, inflammation; vascular dysfunction 
resulting in increased permeability, vascular occlusion and local ischaemia. 
Upregulation of pro-angiogenic and pro-inflammatory factors such as VEGF, insulin 
like growth factor (IGF), angiopoetins-2 (Ang-2), stromal derived factor-1 (SDF-1), 
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basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), tumour 
necrosis factor (TNF) and interleukin-6. Adhesion molecules also play a role in 
inflammation, blood vessel endothelial cells characterictically respond to pro-
inflammatory stimuli and recruit leukocytes by selectively expressing adhesion 
molecules on the surface, such as vascular cell adhesion molecules-1 (VCAM-1), 
intercellular adhesion molecules-1 (ICAM-1) and endothelial cell-selectin (E-selectin) 
(Tunon et al., 2009). 
 
The postulated inflammatory events involved in the endothelial barrier alteration in 
DMO include:  
i. Increased expression of endothelial adhesion molecules such as ICAM, 
VCAM, platelet endothelial cell adhesion molecule (PECAM) and platelet-
selectin (P-Selectin) (Adamis and Berman, 2008; McLeod et al., 1995) 
ii. Adhesion of leucocytes to the endothelium (Miyamoto et al., 1999) 
iii. Release of inflammatory cytokines, vascular permeability factors and growth 
cytokines (Yuuki et al., 2001) 
iv. Alteration of adherens and tight junctional proteins such as vascular 
endothelial-cadherin (VE-Cadherin) and zona occludens-1 (ZO-1), Claudin 
(Harhaj et al., 2006; Murakami et al., 2009) 
v. Infiltration of leucocytes (diapedesis) into retina resulting in the alteration of 
the blood retinal barrier (Muller, 2003) 
 
Increased leucocyte adhesion results in loss of endothelial cells and breakdown of the 
blood retinal barrier (Joussen et al., 2001). 
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Oxidative stress is increased in diabetic retinopathy (Naziroglu and Butterworth, 
2005). The possible causes include increased production of free radicals or impaired 
anti-oxidant defense system in the diabetic retina (Kowluru et al., 2003). 
 
Retina is susceptible to oxidative stress because of its high consumption of oxygen and 
high proportion of polyunsaturated fatty acids (Anderson et al., 1984). Increased 
oxidative stress is associated with increase in retinal basement thickening (Robison et 
al., 2000) and pericyte dropout in diabetic retinopathy (Li et al., 1999). In diabetic 
retina, production of retinal free radicals exceeds their removal; anti-oxidant defence 
systems such as catalase and glutathione peroxidase are subnormal (Kowluru et al., 
1997). Increased reactive oxygen species can activate nitric oxide synthase resulting 
increased nitric oxide (Ho et al., 1999; Miralles et al., 2000). Elevated levels of nitric 
oxide are seen remained in diabetic retina for 12-14 months resulted pericyte loss, 
acellular capillaries and basement membrane thickening (Kowluru et al., 2001).  
 
Retinal nitric oxide has been postulated in ischaemic injury and inhibition of nitric 
oxide synthase can protect the retina from ischaemic damage (Roth, 1997). 
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1.2.3 Investigation of DMO 
 
1.2.3.1 Optical Cohence Tomography 
Optical Cohence Tomography (OCT) is a diagnostic imaging technique that produces 
micrometer resolution, cross sectional images of posterior segment of the eye. It is a 
non-invasive and non-contact imaging modality that provides high resolution 
quantitative measurement of macular thickness. 
 
OCT is based on the principle of low coherence optical interferometry, using near 
infra red light (800-850 nm wavelength) directed to retina and produce backscattered 
light from different layers in the retina. A two dimensional image is constructed and 
displayed in grey or colour scales. White represents areas of high reflectivity whereas 
black represents areas of low reflectivity. 
 
There are 2 types of OCT, Time Domain OCT (TD-OCT) and Spectral Domain OCT 
(SD-OCT). TD-OCT can only obtain 400 A scans per second whereas SD-OCT can 
acquire greater detail over 20,000 A scans per second. SD-OCT scans in a shorter 
time, 0.072 seconds whereas the TD-OCT scans within 1.23 seconds. TD-OCT scans 6 
x 6 mm centered on the fovea. On the other hand, SD-OCT can image the entire 
macula at 2-10 µm in axial (depth) resolution and 20 µm in horizontal resolution. Due 
to faster scanning speed, SD-OCT improved accuracy of retinal thickness and volumes 
measurement. It also offers improving registration; so serial imaging is now possible. 
 
OCT also produce a retinal thickness map with computer software, which can 
automatically detect inner and outer retinal boundaries and produces a macular 
topographic map.  
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In DMO, OCT can be used to help and quantify the amount of oedema present (Figure 
1.4), the proximity and involvement of the foveal region by the oedema as well as the 
response to therapy (Figure 1.5).  
 
thickness as measured by OCT as a secondary endpoint. Com-
parisons with standardized visual acuity have found variable
correlation, however morphological responses to therapy are
well visualized with OCT.72–74 Retinal thickness parameters are
utilized in making re-treatment decisions. In clinical practice,
the use of OCT to follow patients with diabetic macular edema
has increased greatly, particularly for those managed with
intravitreal steroid or anti-VEGF injections.
Figure 130.14, shows the transverse image and macular
thickness assessment in a patient with clinically significant
diabetic macular edema. 
Proliferative Diabetic Retinopathy
Diabetes can lead to the development of extraretinal fibro-
vascular proliferation extending beyond the ILM into the
vitreous. Partial PVD in these cases can lead to the development
of vitreous hemorrhage, macular heterotopia, and tractional
retinal detachment.
Figure 130.15 illustrates the utility of OCT in surgical
planning, with points of adhesion and traction evident.75 Pars-
plana vitrectomy with membrane peeling resulted in an
improved macular anatomy.
Cystoid Macular Edema
Visually significant cystoid macular edema (CME) is one of the
most common reasons for suboptimal visual recovery after
uncomplicated cataract extraction, occurring in ~1–2% of
patients. Occurrence rates may be higher in complicated cases,
aphakia, diabetics, and in patients receiving topical glaucoma
therapy with prostaglandin analogs.76,77 Onset is usually 
6–8 weeks after surgery.
OCT is a noninvasive alternative to fluorescein angiography
in making the diagnosis and following CME. The amount of
intraretinal edema can be quantified. The edema is often con-
tained within cystoid spaces in the outer plexiform layer. OCT
also helps to determine if there is a component of vitreous
Optical Coherence Tomography
C
H
A
P
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R
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30
1731
b
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FIGURE 130.13. (a) Represents a stage IV full thickness macular hole with a PVD (not visible). Notice the signs of severity such as the rounded
contour at the edge of the hole as well as the cystic changes within the retina adjacent to the hole. (b) Successful closure of this macular hole
after pars plana vitrectomy with ILM peeling and intraocular gas tamponade. There is a return to a relatively normal foveal anatomy.
a b
FIGURE 130.14. OCT and corresponding color fundus image of a patient with clinically significant diabetic macular edema. The transverse scan
demonstrates intraretinal edema collecting on the temporal side of the fovea. The topographical image shows the location and extent of the
retinal edema. Notice on the cross-sectional image the hard exudate immediately temporal to the fovea causing a mild shadowing effect.
Ch130-X0016.qxd  12/4/07  3:56 PM  Page 1731
 
Figure 1.4:  OCT and corresponding fundus image in a patient with DMO (Albert et 
al., 2008) 
 
 
Figure 1.5: Retinal thickness map derived from Spectralis OCT. The thickness for 
each nine macular subfields is displayed in both numerical and colour coded formats. 
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1.2.3.2 Fundus Fluorescein Angiography 
Fundus Fluorescein Angiography (FFA) is a method of investigation to detect 
disruption of the blood retinal barrier in order to determine the presence and the extent 
of macular oedema. It is a method in which fluorescein sodium is administered 
intravenously followed by rapid sequence photography of the retina to evaluate its 
circulation.  
 
Normally, the choroidal filling is seen due to fenestrated choriocapillaris allow free 
passing of fluorescein sodium whereas inner blood retinal barrier does not allow 
flourescein leakage. Flourescein can leak out of retinal capillaries into the retina only 
when the capillary endothelium is damaged as in diabetic retinopathy. FFA provides 
enhanced visualization of the geometry and distribution of macular oedema. 
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1.2.4 Treatment Options For Diabetic Macular Oedema 
 
1.2.4.1 Laser Photocoagulation 
Laser photocoagulation,  focal or grid is the standard treatment for DMO. The ETDRS 
group (1987) demonstrated that eyes with macular oedema benefited from immediate 
focal argon laser photocoagulation, which significantly reduces the risk of moderate 
visual loss.  Focal laser most beneficial for eyes meeting criteria for CSMO in which 
incidence of visual loss is decreased by 50% at 3 years (ETDRS, 1985). 
 
The mechanism of DMO resolution after laser therapy is unknown. The possible 
mechanisms include: 
   Laser-induced destruction of oxygen-consuming photoreceptores. Oxygen which 
normally  diffuses from the choriocapillaris into outer retina can diffuse through the 
laser scar  to the inner retina, relieving inner retinal hypoxia. 
    Laser photocoagulation induced retinal pigmented epithelium proliferation that     
produce cytokines to inhibit the VEGF effect. 
 
There is no major adverse effect with laser theraphy except minor loss of visual field 
and occasionally paracentral scotoma. 
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1.2.4.2. Intravitreal Steroids 
Steroids may be useful to treat DMO because of anti-inflammatory effects which 
include decreased inflammatory cell activation. Steroids also have a direct effect on 
endothelial cell junctions maturation and improved blood retinal barrier properties 
(Albert et al., 2008). 
 
Diabetic Retinopathy Clinical Research Network (DRCR.net, 2008) carried out a 
multicenter randomised controlled trial comparing laser photocoagulation with either 1 
mg or 4 mg of intravitreal triamcinolone. In first year, mean visual acuity was better in 
intravitreal triamcinolone (IVTA) groups than in laser group. However, after 2 years 
of treatment, it significantly better in the laser group than in the IVTA groups. The 
main side effect of intravitreal steroid are the development of cataract and elevation of 
intraocular pressure (Gillies et al., 2004). 
 
 
1.2.4.3 Intravitreal VEGF Inhibitors 
VEGF-A is a major mediator of increased retinal permeability. Blockage of VEGF has 
shown to reduce vascular permeability (Hippenstiel et al., 1998). 
 
Many trials and studies have demonstrated that inhibition of VEGF such as 
pegaptanib, bevacizuman and ranibizumab has shown dramatic improvements in 
resolution of DMO and improvement in visual acuity. 
 
The Ranibizumab for Edema of the Macula in Diabetes (READ-2 study, 2010) 
compared the effect of intravitreal 0.5 mg ranibizumab versus laser photocogualation 
versus combined ranibizumab and laser photocoagulation. This study demonstrated 
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that the mean gain in best corrected visual acuity (BCVA) was significantly better in 
the ranibizumab group compared to the laser photocoagulation group. There was no 
significant difference between the ranibizumab group and the combination group 
(Nguyen et al., 2010). 
 
1.2.4.4. Vitrectomy 
It has been postulated that the role of the vitreous in DMO which involves mechanical 
traction of the vitreoretinal interface and the accumulation of factors altering vascular 
permeability such as VEGF  in the vitreous (Bhagat et al., 2009). 
 
Vitrectomy with posterior hyaloid removal or internal limiting membrane  peeling  can 
remove these factors in DMO. The DRCR.net (2010) conducted a study  to evaluate 
vitrectomy for DMO with at least moderate vision loss and vitreomacular traction. The 
study reported that at 6 months, 68% of the vitrectomized eyes had at least a 50% 
reduction in central retinal thickness. Visual acuity improved by 10 letters or more in 
38% of vitrectomized eyes and deteriorated by 10 letters or more in 22% of 
vitrectomized eyes. The complications of vitectomy reported in this study were 
vitreous haemorrhage, elevated intraocular pressure, retinal detachment and 
endophthalmitis. 
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1.2.5 Honey 
 
1.2.5.1 Component of Honey 
Honey is a natural sweetener.	  Honey is produced from many different floral sources 
and its biochemical and pharmacological activities vary depending on its origin and 
processing. Tualang honey is produced by the bees Apis dorsata, which build hives on 
tualang tree.  
 
The composition of honey per 100 g is 300 calories, water (17.1 g), total 
carbohydrates (82.4 g), frustose (38.5 g), glucose (31 g), maltose (7.2 g), sucrose (1.5 
g), total proteins (0.3 g), total fat and cholesterol (0), ph 3.4-6.1 and water content 
(16%-18.3%).	   Honey contains a variety of biologically active compounds such as 
flavonoids, vitamins and anti-oxidants (Chua et al., 2013). Honey also contains 
various enzymes such as oxidase, invertase, amylase and catalase.  
 
 
1.2.5.2 Anti-oxidant Effects of Honey 
Honey contains both aqueous and lipophillic anti-oxidants. Honey with higher water 
content and with darker colour has more anti-oxidants. The anti-oxidants composition 
in honey include monophenolics, flavonoids, polyphenolics and Vitamin C (Schramm 
et al., 2003). This study also  had shown that there was a significant increase of 
plasma total phenolic and plasma anti-oxidant following honey consumption 
(Schramm et al., 2003). Study done by Al-Mamary et al, (2002) had reported on 
composition of honeys and their biological properties as anti-oxidant. Honey can 
increase total anti-oxidant status, activities of glutathione S-transferase and glutathione 
reductase in diabetic rats (Erejuwa et al., 2010). In that animal study also shown 
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reduction of  lipid peroxidation and improvement of  renal morphology in honey 
treated diabetic rats (Erejuwa et al., 2010). Honey can reduce serum fructosamine in 
diabetic that may attributed to anti-oxidant effect (Erejuwa OO, 2011). Fructosamine 
can form AGE which implicated diabetic complications (Selvaraj et al., 2006).  
 
Honey also contains radical scavenger which are able to reduce the imbalance between 
free radical production and anti-oxidant level (Kishore et al., 2011). 
 
With regard to diabetic retinopathy, animal study had shown that combination of 
multiple types of anti-oxidants significantly provide more protection than single anti-
oxidant supplements (Kowluru et al., 2001). Thus, honey with its diversity of anti-
oxidants has a potential as an adjunct treatment for DMO. 
 
 
1.2.5.3 Anti-Inflammatory Effects of Honey 
Honey is also known to have anti-inflammatory properties. A study reported the 
efficacy of honey in the healing of cutaneous wounds of rabbits on the basis of 
histopathological and biochemical changes (Oryan and Zaker, 1998). The honey 
treated rabbits showed less oedema and necrosis, fewer polymorphonuclear cell 
infiltration, better wound contraction and improved epithelialization.  A recent  study 
observed that honey has anti-inflammatory components that reduced corneal 
infiltration by inflammatory cell in alkali chemical eye injury of rabbits (Bashkaran et 
al., 2011).  Honey administered to rats with inflammatory bowel disease  showed 
significantly reduced myeloperoxidase (Bilsel et al., 2002). 
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A study that investigated the effects of honey in animal studies reported that honey 
reduced oedema and pain in the inflammatory tissues. The reduced oedema and pain 
corelates with the inhibition of nitric oxide and prostaglandin E(2) (Kassim et al., 
2010; Owoyele et al., 2011).  
 
 
1.3 RATIONALE OF STUDY 
DMO is a vision threatening complication in DM. Primary standard care of treatment 
for DMO is laser photocoagulation (ETDRS, 1987).  
 
Honey is being recognised to have hypoglycemic effect when combined with 
conventional antidiabetic drug (Al-Waili, 2004; Erejuwa, 2012). Tualang honey was 
reported to reduce hyperglycemia and ameliorates oxidative stress in kidney of 
diabetic rats (Erejuwa et al., 2011). 	  
Since the honey has anti-inflammatory and anti-oxidant properties, therefore it has 
potential therapeutic agent for treatment of DMO. Flavonoid has been investigated and 
showed to reduce inflammmatory factors in diabetic retinopathy (Kowluru et al., 
2014). 
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2. OBJECTIVES 
 
2.1 GENERAL OBJECTIVE 
To evaluate the visual acuity and macular thickness post focal laser with and without 
supplementary honey in DMO  
 
 
2.2 SPECIFIC OBJECTIVE 
2.2.1 To compare LogMAR BCVA post focal laser (pre and post) between those 
with and without supplementary honey in DMO  
 
2.2.2 To compare central macular thickness (CMT) post focal laser (pre and post) 
between those with and without supplementary honey in DMO 
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3. METHODOLOGY 
3.1 STUDY DESIGN 
Prospective randomised control study 
 
3.2 POPULATION, PLACE AND PERIOD OF STUDY  
Study population: All Type 2 DM patients diagnosed with CSMO presented to 
Ophthalmology Clinic and Diabetic Center, Hospital Universiti 
Sains Malaysia (USM), Kelantan 
 
Place of study: Ophthalmology Clinic and Diabetic Center, Hospital USM, 
Kelantan 
 
Period of study:             April 2013 to August 2015 
 
 3.3	  ETHICAL BOARD APPROVAL	  	  This study received approval from the Research and Ethical Committee, School of  
Medical Sciences, USM on 27th March 2013 (Appendix A). 
              
 3.4 FINANCIAL  SUPPORT 
           This study was partially funded by Research University Team grant 
(1001/PPSP/852001) from USM. 
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3.5 SELECTION CRITERIA 
3.5.1 Inclusion Criteria 
i. Type 2 DM patient with CSMO  
ii. Age between 30 to 75 years old 
iii. Clear media to be able to perform acceptable OCT for macular thickness 
measurement 
iv. HbA1c less than 10 % 
 
3.5.2 Exclusion Criteria 
i. CSMO associated with severe non proliferative diabetic retinopathy or 
proliferative diabetic retinopathy  
ii. History of previous laser photocoagulation 
iii. History of intravitreal injection (e.g. steroid, anti-VEGF) 
iv. History of intraocular surgery (e.g. within 6 months post-cataract operation, 
vitreous surgery, retinal detachment surgery)   
v. Patient with any other ocular disease such as glaucoma or pre-existing 
macular disorder such as age related macular degeneration 
vi. History of taking anti-inflammatory agents 
vii. History of taking oral natural herbal health products / dietary supplements 
within 1 month prior to study 
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3.6 SAMPLE SIZE 
Sample size calculation was done using PS software – Power and Sample Size 
calculation version 3.0.43 using the t-test formula. 
α    : level of significance 
SD : standard deviation  
DD : detected difference 
n     : sample size 
 
Objective 1: To compare LogMAR BCVA post focal laser (pre and post) between those 
with and without supplementary honey in DMO  
α : 0.05 
Power : 0.8  
DD : LogMAR -0.12 (the smallest, clinically meaningful difference in mean 
visual acuity (pre and post) between those with and without supplementary 
honey in  DMO  patients that is desired to be detected) 
SD of the change in the LogMAR BCVA (pre and post) in diabetic macular 
oedema : LogMAR 0.18 ( Faghihi et al, 2008) 
n : 20 (for each group) 
20 + 10% dropout = 22 patients  
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Objective 2: To compare CMT post focal laser (pre and post) between those with and 
without supplementary honey in DMO 
α : 0.05 
Power : 0.8 
DD : 48 um (the smallest, clinically meaningful difference in mean macular 
thickness between those with and without supplementary honey in DMO 
patients that is desired to be detected) 
SD of the change in the CMT (pre and post) in DMO patients : 88 um 
(Bandello et al., 2005) 
n : 28 (for each group) 
28 + 10% dropout = 31 patients  
Sample size chosen for this study: 31 patients 
 
3.7 SAMPLING METHOD 
All Type 2 DM patients diagnosed with CSMO attending Ophthalmology Clinic 
Hospital USM between April 2013 and August 2015 that fulfill the criterias were 
recruited into the study. 
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3.8 RANDOMISATION 
New cases of CSMO who fulfilled the selection criterias and given consent for this 
study were randomised into 2 groups (Laser without Honey Group and Laser with 
Honey Group) using randomised opaque envelope technique.  
 
The envelope was prepared with half of the envelopes containing a piece of paper with 
the word ‘Laser without Honey’ and the remaining half stated ‘Laser with Honey’. 
These envelopes were shuffled and kept in a randomisation room in Hospital USM. The 
envelope was drawn for each patient by co-investigator A (CAB). 
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3.9 DEFINITION OF TERMS 
3.9.1 Diabetic Macular Oedema 
            DMO is retinal thickening with or without deposits of intraretinal hard exudates. CSMO 
classification according to EDTRS (1987) is the definition of DMO that was used in this 
study. CSMO is defined as the presence of one or more of the following features: 
• Retinal thickening at or within 500 µm of the center of the macula 
• Exudates at or within 500 µm of the center of the macula with adjacent 
retinal thickening 
• A zone or zones of retinal of thickening of one disc area or larger, any 
part of which is within one disc diameter from the center of the macula      
 
                      
3.9.2 Focal Laser Photocoagulation 
            Focal laser photocoagulation is the standard treatment for DMO. Argon green laser 
applied to all leaking microaneurysms between 500 and 3000 µm (2 disc diameter from 
center of the macula) to cause regression of macular oedema and to prevent progressive 
macular oedema in the future. Laser machine Visular 532S (Carl Zeis) was used in this 
study. 
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3.9.3 Macular Thickness 
 Macular thickness is the volumetric measurement in three dimensions using OCT. 
CMT is the central 1 mm area of a 6 mm mapping as described in ETDRS study 
(ETDRS, 1985) as shown in Figure 3.1. The CMT was taken for analysis in this study. 
OCT Heidelberg Spectralis was used in this study for CMT measurement. 
 
 
!
!
29!
Grid laser photocoagulation is used to treat diffuse type of retinal thickening resulted from 
dilated retinal capillary beds without isolated discrete foci of leakage area. Grid laser causes 
proliferation of pigment epithelial cells followed by improvement in the efficiency of the 
outer blood-retinal barrier which leads to reduction in macular edema (Bandello et al., 1999).  
 
3.11.4. Macular Thickness 
Macular thickness is the volumetric measurement of the central retinal thickness in three 
dimensions. Optical Coherence Tomography (OCT) enables macular thickness to be 
measured accurately and able to detect small changes in retinal thickness (Huang et al., 
1991). Central macular thickness (CMT) is the central 1 mm area of a 6 mm Fast Macular 
mapping as described in the ETDRS study (ETDRS, 1985) as shown in Figure 3.1. The CMT 
was taken for analysis in this study. 
 
Figure 3.1 : Central Macular Thickness (CMT) area of 1 mm as described by ETDRS Study. 
 
 
 
Figure 3.1: Central macular thickness (CMT) area of 1 mm (ETDRS, 1985) 
 
 
 
 
 
 
 
 
 
 
 
 
